- Home
- GXAI vs KZIA Comparison
GXAI vs KZIA Comparison
Compare GXAI & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GXAI
- KZIA
- Stock Information
- Founded
- GXAI 2021
- KZIA 1994
- Country
- GXAI United States
- KZIA Australia
- Employees
- GXAI N/A
- KZIA N/A
- Industry
- GXAI
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- GXAI
- KZIA Health Care
- Exchange
- GXAI Nasdaq
- KZIA Nasdaq
- Market Cap
- GXAI 8.0M
- KZIA 6.0M
- IPO Year
- GXAI 2023
- KZIA 1999
- Fundamental
- Price
- GXAI $1.20
- KZIA $0.96
- Analyst Decision
- GXAI
- KZIA Strong Buy
- Analyst Count
- GXAI 0
- KZIA 2
- Target Price
- GXAI N/A
- KZIA $11.50
- AVG Volume (30 Days)
- GXAI 747.8K
- KZIA 390.8K
- Earning Date
- GXAI 03-26-2025
- KZIA 03-26-2025
- Dividend Yield
- GXAI N/A
- KZIA N/A
- EPS Growth
- GXAI N/A
- KZIA N/A
- EPS
- GXAI N/A
- KZIA N/A
- Revenue
- GXAI $2,979.00
- KZIA $1,655,324.00
- Revenue This Year
- GXAI N/A
- KZIA N/A
- Revenue Next Year
- GXAI N/A
- KZIA N/A
- P/E Ratio
- GXAI N/A
- KZIA N/A
- Revenue Growth
- GXAI N/A
- KZIA 248000.00
- 52 Week Low
- GXAI $1.01
- KZIA $0.76
- 52 Week High
- GXAI $16.27
- KZIA $15.80
- Technical
- Relative Strength Index (RSI)
- GXAI 39.54
- KZIA 42.17
- Support Level
- GXAI $1.10
- KZIA $0.78
- Resistance Level
- GXAI $1.43
- KZIA $1.44
- Average True Range (ATR)
- GXAI 0.14
- KZIA 0.12
- MACD
- GXAI 0.01
- KZIA 0.06
- Stochastic Oscillator
- GXAI 22.10
- KZIA 21.54
About GXAI Gaxos.ai Inc.
Gaxos.AI Inc is revolutionizing the way humans interact with artificial intelligence. The company offers applications related to mental and physical well-being, coaching, and gaming. The group is committed to tackling contemporary challenges such as how to live healthier and how to live longer. In addition to offering human-centered solutions, the company uses empathetic and AI technologies.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.